These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
176 related articles for article (PubMed ID: 23295928)
1. Single- and multiple-dose study to determine the safety, tolerability, and pharmacokinetics of ceftaroline fosamil in combination with avibactam in healthy subjects. Riccobene TA; Su SF; Rank D Antimicrob Agents Chemother; 2013 Mar; 57(3):1496-504. PubMed ID: 23295928 [TBL] [Abstract][Full Text] [Related]
2. Evaluation of the pharmacokinetics and safety of single and multiple ceftaroline fosamil infusions in healthy Chinese and Western subjects. Yang L; Sunzel M; Xu P; Edeki T; Wilson D; Li J; Li H Int J Clin Pharmacol Ther; 2015 Aug; 53(8):681-91. PubMed ID: 26152131 [TBL] [Abstract][Full Text] [Related]
3. Randomized, placebo-controlled study to assess the impact on QT/QTc interval of supratherapeutic doses of ceftazidime-avibactam or ceftaroline fosamil-avibactam. Das S; Armstrong J; Mathews D; Li J; Edeki T J Clin Pharmacol; 2014 Mar; 54(3):331-40. PubMed ID: 24150927 [TBL] [Abstract][Full Text] [Related]
4. An open-label, non-randomised, phase 1, single-dose study to assess the pharmacokinetics of ceftaroline in patients with end-stage renal disease requiring intermittent haemodialysis. Sunzel M; Learoyd M; Li J; Li Y; Ngo N; Edeki T Int J Antimicrob Agents; 2015 Dec; 46(6):682-8. PubMed ID: 26545441 [TBL] [Abstract][Full Text] [Related]
5. Safety, local tolerability and pharmacokinetics of ceftaroline fosamil administered in a reduced infusion volume. Edeki T; Kujacic M; Broadhurst H; Li J; Sunzel M Br J Clin Pharmacol; 2014 Dec; 78(6):1291-7. PubMed ID: 25041494 [TBL] [Abstract][Full Text] [Related]
6. Safety and pharmacokinetics of single and multiple ascending doses of avibactam alone and in combination with ceftazidime in healthy male volunteers: results of two randomized, placebo-controlled studies. Merdjan H; Rangaraju M; Tarral A Clin Drug Investig; 2015 May; 35(5):307-17. PubMed ID: 25813217 [TBL] [Abstract][Full Text] [Related]
7. Single- and Repeated-Dose Pharmacokinetics of Ceftaroline in Plasma and Soft Tissues of Healthy Volunteers for Two Different Dosing Regimens of Ceftaroline Fosamil. Matzneller P; Lackner E; Lagler H; Wulkersdorfer B; Österreicher Z; Zeitlinger M Antimicrob Agents Chemother; 2016 Jun; 60(6):3617-25. PubMed ID: 27044549 [TBL] [Abstract][Full Text] [Related]
8. Summary of the safety and tolerability of two treatment regimens of ceftaroline fosamil: 600 mg every 8 h versus 600 mg every 12 h. Cheng K; Pypstra R; Yan JL; Hammond J J Antimicrob Chemother; 2019 Apr; 74(4):1086-1091. PubMed ID: 30597021 [TBL] [Abstract][Full Text] [Related]
9. Supporting the ceftaroline fosamil/avibactam Enterobacteriaceae breakpoint determination using humanised in vivo exposures in a thigh model. Bhalodi AA; Crandon JL; Williams G; Nicolau DP Int J Antimicrob Agents; 2014 Dec; 44(6):508-13. PubMed ID: 25278330 [TBL] [Abstract][Full Text] [Related]
10. Ceftaroline fosamil doses and breakpoints for Staphylococcus aureus in complicated skin and soft tissue infections. Das S; Li J; Iaconis J; Zhou D; Stone GG; Yan JL; Melnick D J Antimicrob Chemother; 2019 Feb; 74(2):425-431. PubMed ID: 30380060 [TBL] [Abstract][Full Text] [Related]
12. Integrated safety summary of FOCUS 1 and FOCUS 2 trials: Phase III randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with community-acquired pneumonia. Rank DR; Friedland HD; Laudano JB J Antimicrob Chemother; 2011 Apr; 66 Suppl 3():iii53-9. PubMed ID: 21482570 [TBL] [Abstract][Full Text] [Related]
13. A series of pharmacokinetic studies of ceftaroline fosamil in select populations: normal subjects, healthy elderly subjects, and subjects with renal impairment or end-stage renal disease requiring hemodialysis. Riccobene T; Jakate A; Rank D J Clin Pharmacol; 2014 Jul; 54(7):742-52. PubMed ID: 24431097 [TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetics of ceftaroline in patients with acute bacterial skin and skin structure infections or community-acquired bacterial pneumonia. Van Wart SA; Forrest A; Khariton T; Rubino CM; Bhavnani SM; Reynolds DK; Riccobene T; Ambrose PG J Clin Pharmacol; 2013 Nov; 53(11):1155-67. PubMed ID: 23907740 [TBL] [Abstract][Full Text] [Related]
15. Phase 2 Study of the Safety, Pharmacokinetics and Efficacy of Ceftaroline Fosamil in Neonates and Very Young Infants With Late-onset Sepsis. Bradley JS; Stone GG; Chan PLS; Raber SR; Riccobene T; Mas Casullo V; Yan JL; Hendrick VM; Hammond J; Leister-Tebbe HK Pediatr Infect Dis J; 2020 May; 39(5):411-418. PubMed ID: 32091493 [TBL] [Abstract][Full Text] [Related]
16. Ceftaroline fosamil therapy in patients with acute bacterial skin and skin-structure infections with systemic inflammatory signs: A retrospective dose comparison across three pivotal trials. Corey GR; Wilcox MH; Gonzalez J; Jandourek A; Wilson DJ; Friedland HD; Das S; Iaconis J; Dryden M Int J Antimicrob Agents; 2019 Jun; 53(6):830-837. PubMed ID: 30716446 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of the effect of a supratherapeutic dose of intravenous ceftaroline fosamil on the corrected QT interval. Riccobene TA; Rekeda L; Rank D; Llorens L Antimicrob Agents Chemother; 2013 Apr; 57(4):1777-83. PubMed ID: 23357764 [TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic and Pharmacodynamic Target Attainment in Adult and Pediatric Patients Following Administration of Ceftaroline Fosamil as a 5-Minute Infusion. Riccobene TA; Carrothers TJ; Knebel W; Raber S; Chan PLS Clin Pharmacol Drug Dev; 2021 Apr; 10(4):420-427. PubMed ID: 33465279 [TBL] [Abstract][Full Text] [Related]
19. The pharmacodynamics of avibactam in combination with ceftaroline or ceftazidime against β-lactamase-producing Enterobacteriaceae studied in an in vitro model of infection. MacGowan A; Tomaselli S; Noel A; Bowker K J Antimicrob Chemother; 2017 Mar; 72(3):762-769. PubMed ID: 28039276 [TBL] [Abstract][Full Text] [Related]
20. FOCUS 1: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. File TM; Low DE; Eckburg PB; Talbot GH; Friedland HD; Lee J; Llorens L; Critchley IA; Thye DA; J Antimicrob Chemother; 2011 Apr; 66 Suppl 3():iii19-32. PubMed ID: 21482566 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]